Erratum: Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4/6 Inhibition Elicits Unique Vulnerabilities (Cell Reports (2016) 14(5) (979–990), (S2211124715015508), (10.1016/j.celrep.2015.12.094));Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4/6 Inhibition Elicits Unique Vulnerabilities

Cell Reports

Volumn 14, Issue 5, 2016, Pages 979-990

  Franco, Jorge ^a   Balaji, Uthra ^a   Freinkman, Elizaveta ^c   Witkiewicz, Agnieszka K ^a,b   Knudsen, Erik S ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ADENOSINE TRIPHOSPHATE; ALPELISIB; BUPARLISIB; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR; DACTOLISIB; EVEROLIMUS; LY 2853219; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; PALBOCICLIB; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; RETINOBLASTOMA PROTEIN; RIBOCICLIB; RIDAFOROLIMUS; SELUMETINIB; TORIN 1; UNCLASSIFIED DRUG; PROTEIN KINASE INHIBITOR; TARGET OF RAPAMYCIN KINASE;

AEROBIC METABOLISM; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL KILLING; CONTROLLED STUDY; CYTOSTASIS; ENZYME INHIBITION; GLYCOLYSIS; HUMAN; HUMAN CELL; METABOLIC REPROGRAMMING; METABOLISM; MITOCHONDRION; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; TUMOR CELL; TUMOR VOLUME; TUMOR XENOGRAFT; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; PANCREAS TUMOR; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; ULTRASTRUCTURE;

CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; HUMANS; MITOCHONDRIA; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; REACTIVE OXYGEN SPECIES; RETINOBLASTOMA PROTEIN; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84957959125     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2020.107793     Document Type: Erratum

References (53)

1. Ambrus A.M., Islam A.B., Holmes K.B., Moon N.S., Lopez-Bigas N., Benevolenskaya E.V., Frolov M.V. Loss of dE2F compromises mitochondrial function. Dev. Cell 2013, 27:438-451.
2. Asghar U., Witkiewicz A.K., Turner N.C., Knudsen E.S. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat. Rev. Drug Discov. 2015, 14:130-146.
3. Baek G., Tse Y.F., Hu Z., Cox D., Buboltz N., McCue P., Yeo C.J., White M.A., DeBerardinis R.J., Knudsen E.S., Witkiewicz A.K. MCT4 defines a glycolytic subtype of pancreatic cancer with poor prognosis and unique metabolic dependencies. Cell Rep. 2014, 9:2233-2249.
4. Benevolenskaya E.V., Frolov M.V. Emerging links between E2F control and mitochondrial function. Cancer Res. 2015, 75:619-623.
5. Blanchet E., Annicotte J.S., Lagarrigue S., Aguilar V., Clapé C., Chavey C., Fritz V., Casas F., Apparailly F., Auwerx J., Fajas L. E2F transcription factor-regulates oxidative metabolism. Nat. Cell Biol. 2011, 13:1146-1152.
6. Brunelle J.K., Shroff E.H., Perlman H., Strasser A., Moraes C.T., Flavell R.A., Danial N.N., Keith B., Thompson C.B., Chandel N.S. Loss of Mcl-protein and inhibition of electron transport chain together induce anoxic cell death. Mol. Cell. Biol. 2007, 27:1222-1235.
7. Bryant K.L., Mancias J.D., Kimmelman A.C., Der C.J. KRAS: feeding pancreatic cancer proliferation. Trends Biochem. Sci. 2014, 39:91-100.
8. Cai L., Tu B.P. Driving the cell cycle through metabolism. Annu. Rev. Cell Dev. Biol. 2012, 28:59-87.
9. Chicas A., Wang X., Zhang C., McCurrach M., Zhao Z., Mert O., Dickins R.A., Narita M., Zhang M., Lowe S.W. Dissecting the unique role of the retinoblastoma tumor suppressor during cellular senescence. Cancer Cell 2010, 17:376-387.
10. Clem B.F., Chesney J. Molecular pathways: regulation of metabolism by RB. Clin. Cancer Res. 2012, 18:6096-6100.
11. Datar S.A., Jacobs H.W., de la Cruz A.F., Lehner C.F., Edgar B.A. The Drosophila cyclin D-Cdk4 complex promotes cellular growth. EMBO J. 2000, 19:4543-4554.
12. Dean J.L., Thangavel C., McClendon A.K., Reed C.A., Knudsen E.S. Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure. Oncogene 2010, 29:4018-4032.
13. Dickson M.A. Molecular pathways: CDK4 inhibitors for cancer therapy. Clin. Cancer Res. 2014, 20:3379-3383.
14. Franco J., Witkiewicz A.K., Knudsen E.S. CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer. Oncotarget 2014, 5:6512-6525.
15. Fry D.W., Harvey P.J., Keller P.R., Elliott W.L., Meade M., Trachet E., Albassam M., Zheng X., Leopold W.R., Pryer N.K., Toogood P.L. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol. Cancer Ther. 2004, 3:1427-1438.
16. Galluzzi L., Kepp O., Vander Heiden M.G., Kroemer G. Metabolic targets for cancer therapy. Nat. Rev. Drug Discov. 2013, 12:829-846.
17. Gorrini C., Harris I.S., Mak T.W. Modulation of oxidative stress as an anticancer strategy. Nat. Rev. Drug Discov. 2013, 12:931-947.
18. Heilmann A.M., Perera R.M., Ecker V., Nicolay B.N., Bardeesy N., Benes C.H., Dyson N.J. CDK4/6 and IGF1 receptor inhibitors synergize to suppress the growth of p16INK4A-deficient pancreatic cancers. Cancer Res. 2014, 74:3947-3958.
19. Hilgendorf K.I., Leshchiner E.S., Nedelcu S., Maynard M.A., Calo E., Ianari A., Walensky L.D., Lees J.A. The retinoblastoma protein induces apoptosis directly at the mitochondria. Genes Dev. 2013, 27:1003-1015.
20. Knudsen E.S., Wang J.Y. Dual mechanisms for the inhibition of E2F binding to RB by cyclin-dependent kinase-mediated RB phosphorylation. Mol. Cell. Biol. 1997, 17:5771-5783.
21. Lamb J., Ramaswamy S., Ford H.L., Contreras B., Martinez R.V., Kittrell F.S., Zahnow C.A., Patterson N., Golub T.R., Ewen M.E. A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell 2003, 114:323-334.
22. LaPak K.M., Burd C.E. The molecular balancing act of p16(INK4a) in cancer and aging. Mol. Cancer Res. 2014, 12:167-183.
23. Laplante M., Sabatini D.M. mTOR signaling at a glance. J. Cell Sci. 2009, 122:3589-3594.
24. Laplante M., Sabatini D.M. mTOR Signaling. Cold Spring Harb. Perspect. Biol. 2012, 4:a011593.
25. Leonard J.P., LaCasce A.S., Smith M.R., Noy A., Chirieac L.R., Rodig S.J., Yu J.Q., Vallabhajosula S., Schoder H., English P., et al. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood 2012, 119:4597-4607.
26. Liu F., Korc M. Cdk4/6 inhibition induces epithelial-mesenchymal transition and enhances invasiveness in pancreatic cancer cells. Mol. Cancer Ther. 2012, 11:2138-2148.
27. Lopez-Mejia I.C., Fajas L. Cell cycle regulation of mitochondrial function. Curr. Opin. Cell Biol. 2015, 33:19-25.
28. Lyssiotis C.A., Son J., Cantley L.C., Kimmelman A.C. Pancreatic cancers rely on a novel glutamine metabolism pathway to maintain redox balance. Cell Cycle 2013, 12:1987-1988.
29. Maitra A., Hruban R.H. Pancreatic cancer. Annu. Rev. Pathol. 2008, 3:157-188.
30. Nicolay B.N., Gameiro P.A., Tschöp K., Korenjak M., Heilmann A.M., Asara J.M., Stephanopoulos G., Iliopoulos O., Dyson N.J. Loss of RBF1 changes glutamine catabolism. Genes Dev. 2013, 27:182-196.
31. Nicolay B.N., Danielian P.S., Kottakis F., Lapek J.D., Sanidas I., Miles W.O., Dehnad M., Tschöp K., Gierut J.J., Manning A.L., et al. Proteomic analysis of pRb loss highlights a signature of decreased mitochondrial oxidative phosphorylation. Genes Dev. 2015, 29:1875-1889.
32. Oltersdorf T., Elmore S.W., Shoemaker A.R., Armstrong R.C., Augeri D.J., Belli B.A., Bruncko M., Deckwerth T.L., Dinges J., Hajduk P.J., et al. An inhibitor of Bcl-family proteins induces regression of solid tumours. Nature 2005, 435:677-681.
33. Paulson A.S., Tran Cao H.S., Tempero M.A., Lowy A.M. Therapeutic advances in pancreatic cancer. Gastroenterology 2013, 144:1316-1326.
34. Reynolds M.R., Lane A.N., Robertson B., Kemp S., Liu Y., Hill B.G., Dean D.C., Clem B.F. Control of glutamine metabolism by the tumor suppressor Rb. Oncogene 2014, 33:556-566.
35. Roberts P.J., Bisi J.E., Strum J.C., Combest A.J., Darr D.B., Usary J.E., Zamboni W.C., Wong K.K., Perou C.M., Sharpless N.E. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. J. Natl. Cancer Inst. 2012, 104:476-487.
36. Sabharwal S.S., Schumacker P.T. Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles' heel?. Nat. Rev. Cancer 2014, 14:709-721.
37. Saif M.W. Advancements in the management of pancreatic cancer: 2013. JOP 2013, 14:112-118.
38. Sancak Y., Peterson T.R., Shaul Y.D., Lindquist R.A., Thoreen C.C., Bar-Peled L., Sabatini D.M. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 2008, 320:1496-1501.
39. Serrano M., Gómez-Lahoz E., DePinho R.A., Beach D., Bar-Sagi D. Inhibition of ras-induced proliferation and cellular transformation by p16INK4. Science 1995, 267:249-252.
40. Serrano M., Lin A.W., McCurrach M.E., Beach D., Lowe S.W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997, 88:593-602.
41. Sousa C.M., Kimmelman A.C. The complex landscape of pancreatic cancer metabolism. Carcinogenesis 2014, 35:1441-1450.
42. Thomas L.W., Lam C., Edwards S.W. Mcl-1; the molecular regulation of protein function. FEBS Lett. 2010, 584:2981-2989.
43. Tibes R., Qiu Y., Lu Y., Hennessy B., Andreeff M., Mills G.B., Kornblau S.M. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol. Cancer Ther. 2006, 5:2512-2521.
44. Vander Heiden M.G. Targeting cancer metabolism: a therapeutic window opens. Nat. Rev. Drug Discov. 2011, 10:671-684.
45. Váraljai R., Islam A.B., Beshiri M.L., Rehman J., Lopez-Bigas N., Benevolenskaya E.V. Increased mitochondrial function downstream from KDM5A histone demethylase rescues differentiation in pRB-deficient cells. Genes Dev. 2015, 29:1817-1834.
46. Viale A., Pettazzoni P., Lyssiotis C.A., Ying H., Sánchez N., Marchesini M., Carugo A., Green T., Seth S., Giuliani V., et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature 2014, 514:628-632.
47. Vincent A., Herman J., Schulick R., Hruban R.H., Goggins M. Pancreatic cancer. Lancet 2011, 378:607-620.
48. Vora S.R., Juric D., Kim N., Mino-Kenudson M., Huynh T., Costa C., Lockerman E.L., Pollack S.F., Liu M., Li X., et al. CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. Cancer Cell 2014, 26:136-149.
49. Wang C., Li Z., Lu Y., Du R., Katiyar S., Yang J., Fu M., Leader J.E., Quong A., Novikoff P.M., Pestell R.G. Cyclin D1 repression of nuclear respiratory factor 1 integrates nuclear DNA synthesis and mitochondrial function. Proc. Natl. Acad. Sci. USA 2006, 103:11567-11572.
50. Witkiewicz A.K., Knudsen K.E., Dicker A.P., Knudsen E.S. The meaning of p16(ink4a) expression in tumors: functional significance, clinical associations and future developments. Cell Cycle 2011, 10:2497-2503.
51. Witkiewicz A.K., Borja N.A., Franco J., Brody J.R., Yeo C.J., Mansour J., Choti M.A., McCue P., Knudsen E.S. Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer. Oncotarget 2015, 6:15788-15801.
52. Witkiewicz A.K., McMillan E.A., Balaji U., Baek G., Lin W.C., Mansour J., Mollaee M., Wagner K.U., Koduru P., Yopp A., et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat. Commun. 2015, 6:6744.
53. Ying H., Kimmelman A.C., Lyssiotis C.A., Hua S., Chu G.C., Fletcher-Sananikone E., Locasale J.W., Son J., Zhang H., Coloff J.L., et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 2012, 149:656-670.